Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 8

1.037 Posts
Pagina: «« 1 ... 32 33 34 35 36 ... 52 »» | Laatste | Omlaag ↓
  1. [verwijderd] 5 maart 2007 12:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    Connex wat zeur je nu steeds met merimack
    De rekening word toch steeds om gezet in private investment dat is de aanloop naar overname Merimack door gtcb ze hebben al een aardige belang in die toko

    Nog even en we kunnen in de zon liggen met al die winst vooruitzichten
    Ze hebben al een plekje voor mij gereserveerd
    Mooi uitzicht tussen al die bomen

    www.merimack.com/
    ik zie alleen maar wolken, heel toepasselijk,
    wat heb ik nou weer gemist wishbone of slaat de fantasie op hol?

    toen ik tn sprak en het had over merrimack, was ie wat vaag, wellicht 1 toepassing goedgekeurd sprak hij, dat is maar een onderdeel,

    vond dat een vreemde opmerking, daar ik was teruggebeld door merrimack en zei meldden me, dat dit onderdeel veruit t meest interessante onderdeel was van de 3.

  4. [verwijderd] 5 maart 2007 13:42

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    The Wishbone schreef:

    No Pre-Market trades have been reported for this security.
    Moet nog komen

    denk ik

    Vanaf 1400 uur tot 15.30 uur komen ze(if any).
  6. [verwijderd] 5 maart 2007 13:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Beurs-kneus schreef:

    Pre-Market trade data will be posted from 8:15 a.m dwz 14.45u onze tijd. (NL/BE)
    Hoezo ,zit NY opeens 6 1/2 uur bij ons vandaan?
  7. ludwig mack 5 maart 2007 13:53

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 10 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    controverse schreef:

    [quote=semperfidelis]
    We zijn wel in het nieuws, zelfs breaking news:

    www.genengnews.com/bioprocessing/

    Keep faith!
    [/quote]

    Goede morgen,

    Wat mij opvalt in dit bericht is het tijdstip van plaatsing 03.33u. Dus tijdens de handel in New York en niet na sluiting.

    kan zijn de tijd dat gtcb het heeft opgesteld, klaar om later te verspreiden na beurs. je kunt er denk ik niets meer over zeggen, ik bedoel, het heeft niet meer dan dat als betekenis.
  8. [verwijderd] 5 maart 2007 14:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    robertix schreef:

    [quote=Beurs-kneus]
    Pre-Market trade data will be posted from 8:15 a.m dwz 14.45u onze tijd. (NL/BE)
    [/quote]
    Hoezo ,zit NY opeens 6 1/2 uur bij ons vandaan?
    foutje Bedankt....
  9. [verwijderd] 5 maart 2007 14:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC BioTherapeutics 4Q Loss 10c/Shr>GTCBLast update: 3/5/2007 8:00:55 AM(MORE TO FOLLOW) Dow Jones NewswiresMarch 05, 2007 08:00 ET (13:00 GMT)
  11. [verwijderd] 5 maart 2007 14:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC Biotherapeutics Reports Fourth Quarter and Year End 2006 Financial ResultsLast update: 3/5/2007 8:00:37 AMFRAMINGHAM, Mass., Mar 05, 2007 (BUSINESS WIRE) -- GTC Biotherapeutics, Inc. (GTCB) reported today its financial results for the fourth quarter and year ended December 31, 2006. The net loss for the fourth quarter of 2006 was $7.4 million, or $0.10 per share, compared to $8.3 million, or $0.15 per share in the fourth quarter of 2005. The net loss for the 2006 financial year was $35.3 million, or $0.53 per share, compared to $30.1 million, or $0.62 per share, for the 2005 financial year. "GTC went through a transformation in 2006, catalyzed by the approval of ATryn(R) in Europe, the first approval of a transgenically produced therapeutic product anywhere in the world," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "We have two important partner relationships with LEO Pharma A/S and LFB Biotechnologies which enable us to further develop ATryn(R) and expand our portfolio of recombinant plasma proteins. We now have a portfolio of proprietary products that are capable of driving significant future value and we have strengthened our balance sheet. As we move forward through 2007, we intend to increase our strategic focus on partnering activities to provide additional resources and momentum to our product development programs." ATryn(R), our recombinant form of human antithrombin, was approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. Our partner LEO is planning to introduce the ATryn(R) product at the International Society of Thrombosis and Haemostasis conference in July 2007. In addition, LEO has obtained Scientific Advice from the European Medicines Agency on the design of a Phase II dose ranging study for the treatment of disseminated intravascular coagulation, or DIC, associated with severe sepsis. Clinical sites to initiate patient enrollment for this Phase II study are being opened. We have rights to use the Phase II data outside the LEO territories of Europe, Canada, and the Middle East, and we will receive payment from LEO for the product used in its clinical studies. In the United States, we are continuing our pivotal Phase III active and historical comparison trials of ATryn(R) in the hereditary deficiency indication and we expect to file for approval with the Food and Drug Administration around the end of 2007. We intend to develop ATryn(R) in Japan through further partnering and have begun initial discussions with potential interested partners. We believe that the worldwide market potential of ATryn(R) is $500 million to $700 million, primarily in acquired antithrombin deficiency indications such as DIC. Antithrombin is a plasma protein with anticoagulant and anti-inflammatory properties. We have developed goats that have the human antithrombin gene linked to a milk-protein promoting gene so that they express this protein in their milk. This transgenic approach provides the opportunity to produce recombinant forms of proteins, such as antithrombin, that are difficult to express in economically viable quantities in conventional production systems. We entered a strategic collaboration with LFB Biotechnologies, or LFB, in late 2006 that includes development of recombinant human factor VIIa, or rhFVIIa, a clotting factor in coagulation. The first indication planned for this program is in the treatment of type A and type B hemophilia where patients have developed inhibitors to clotting factors VIII or IX. An independent analyst report estimates the total worldwide market for rhFVIIa will be $2 billion by 2012, which is the year when the patents on the current marketed product, NovoSeven(R), expire. The strategic collaboration with LFB includes potential development of additional recombinant human plasma proteins and monoclonal antibodies. An evaluation of these opportunities is in process. Our portfolio of recombinant plasma proteins includes recombinant human alpha-1 antitrypsin, for which we have already established a production herd and which is in preclinical development. Last week, we entered into an agreement with PharmAthene under which we will provide process development and clinical supply manufacturing services for Protexia(R), a recombinant form of human butyrylcholinesterase produced in the milk of transgenic goats. Protexia(R) is being developed by PharmAthene as a pre- and post-exposure therapy for military or civilian victims of a chemical nerve agent attack. The Protexia(R) program, similar to the continuing supply relationship for Merrimack Pharmaceuticals' MM-093 product, will use our transgenic production technology to enable development of the partner's protein that does not express in economically viable quantities in traditional bioreactor-based methods. We also intend to develop through a partnering relationship our monoclonal antibody to the CD137 receptor in the human immune system. This antibody has been reported to demonstrate potential therapeutic value in preclinical models of solid tumors and autoimmune diseases. We have established production animals and are proceeding to preclinical development to support clinical studies. Cash Position We ended 2006 with approximately $43.8 million of cash and marketable securities. The third and final equity investment by LFB on January 3, 2007, as well as payments from LEO for delivery in January 2007 of Phase II clinical material that was manufactured in late 2006, provided us with additional cash and marketable securities totaling about $7 million, which on a pro forma basis would put our year-end cash and marketable securities at approximately $51 million. During 2006, we had a net increase of $7.6 million in cash and marketable securities including financing activities. We used $24.6 million of cash in operations. For 2007, we expect our net cash use to be in the range of $26 to 29 million. The net cash use includes forecasted sales of ATryn(R) in the approved indication and to LEO for the DIC study, as well as receipts from new and existing contracts and planned research and development activities in support of ATryn(R) and our other programs. The Phase II DIC clinical study activities in 2007 will be conducted and funded by LEO. In December 2006, we completed a re-financing of our senior debt facility with GE Capital. This refinancing provided an additional $2.8 million of proceeds while extending the amortization period for $8 million of the debt facility, which reduces our annual debt service. After the refinancing, we had a total of $10 million of debt outstanding with GE. Financial Results Revenues were $2.8 million for the fourth quarter of 2006, compared with $0.6 million in the fourth quarter of 2005. Revenues for 2006 were $6.1 million, a 48% increase from $4.2 million in 2005. Revenues increased primarily due to shipment of initial clinical supply material to LEO for the DIC Phase II study as well as amortization of the milestone payments previously received. Costs of revenue and operating expenses were $41.8 million for 2006, 23% higher than the $33.9 million in 2005, primarily due to increased research and development expenses, which totaled $25.4 million for 2006, an increase of 20% over the $21.1 million in 2005. The increase was driven primarily by validation costs and costs associated wi
  14. [verwijderd] 5 maart 2007 14:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vertaling door babelfish
    Wij zijn van plan ATryn® in Japan door verder partnering te ontwikkelen en met aanvankelijke besprekingen met potentieel interessante partners begonnen. Wij geloven dat het marktpotentieel wereldwijd van ATryn® $500 miljoen tot $700 miljoen, hoofdzakelijk in verworven antithrombin deficiëntieaanwijzingen zoals DIC is.
  15. [verwijderd] 5 maart 2007 14:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Iets betere cijfers dan dan gemiddelde verwachting dus.

    News

    GTC Biotherapeutics Q4 Loss Per Share Narrows - Quick Facts

    (RTTNews) - GTC Biotherapeutics, Inc. (GTCB) on Monday reported a net loss of $7.4 million or $0.10 per share for the fourth quarter, narrower than $8.3 million or $0.15 per share in the prior year quarter.

    On average, four analysts polled by First Call/Thomson Financial expected the company to report loss of $0.14 per share.

    Quarterly revenues increased to $2.8 million from $0.6 million a year ago. Four Wall Street analysts estimated revenues of $740 thousand for the quarter.














  17. [verwijderd] 5 maart 2007 14:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik ben wel erg benieuwd met wie ze in bespreking zijn
    Zo als je ziet praat men in meervoud (interessante partners)
    500/700 miljoen marktwaarde We kijken niet op een paar honderd zaltochwelniettemin 1 biljoen gaan worden.

    quote:

    The Wishbone schreef:

    Vertaling door babelfish
    Wij zijn van plan ATryn® in Japan door verder partnering te ontwikkelen en met aanvankelijke besprekingen met potentieel interessante partners begonnen. Wij geloven dat het marktpotentieel wereldwijd van ATryn® $500 miljoen tot $700 miljoen, hoofdzakelijk in verworven antithrombin deficiëntieaanwijzingen zoals DIC is.
1.037 Posts
Pagina: «« 1 ... 32 33 34 35 36 ... 52 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.126
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.256
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.903
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.855
Aedifica 3 927
Aegon 3.258 323.107
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.066
Ahold 3.538 74.353
Air France - KLM 1.025 35.300
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.053
Alfen 16 25.340
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.058
AMG 972 134.515
AMS 3 73
Amsterdam Commodities 305 6.746
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.068
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.017
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.360
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.644
ASML 1.766 110.654
ASR Nederland 21 4.515
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.161
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449

Macro & Bedrijfsagenda

  1. 03 april

    1. Inkoopmanagersindex diensten maart def. (Jap)
    2. Inkoopmanagersindex diensten (Caixin) maart (Chi)
    3. Inkoopmanagersindex diensten maart def. (Dld)
    4. Inkoopmanagersindex diensten maart def. (eur)
    5. Producentenprijzen februari (eur)
    6. Acuity Brands Q2-cijfers
    7. Handelsbalans februari (VS)
    8. Steunaanvragen - wekelijks (VS)
    9. Inkoopmanagersindex diensten (S&P) maart def. (VS)
    10. Inkoopmanagersindex diensten (ISM) maart def. (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda